|
1
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vasudev NS and Reynolds AR:
Anti-angiogenic therapy for cancer: Current progress, unresolved
questions and future directions. Angiogenesis. 17:471–494. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Brinda BJ, Viganego F, Vo T, Dolan D and
Fradley MG: Anti-VEGF-induced hypertension: A review of
pathophysiology and treatment options. Curr Treat Options
Cardiovasc Med. 18:332016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Eskens FA and Verweij J: The clinical
toxicity profile of vascular endothelial growth factor (VEGF) and
vascular endothelial growth factor receptor (VEGFR) targeting
angiogenesis inhibitors; A review. Eur J Cancer. 42:3127–3139.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Abi Aad S, Pierce M, Barmaimon G, Farhat
FS, Benjo A and Mouhayar E: Hypertension induced by
chemotherapeutic and immunosuppresive agents: A new challenge. Crit
Rev Oncol Hematol. 93:28–35. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Neagoe PE, Lemieux C and Sirois MG:
Vascular endothelial growth factor (VEGF)-A165-induced prostacyclin
synthesis requires the activation of VEGF receptor-1 and −2
heterodimer. J Biol Chem. 280:9904–9912. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Neves KB, Rios FJ, Jones R, Evans TRJ,
Montezano AC and Touyz RM: Microparticles from vascular endothelial
growth factor pathway inhibitor-treated cancer patients mediate
endothelial cell injury. Cardiovasc Res. 115:978–988. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hasinoff BB and Patel D: Mechanisms of
myocyte cytotoxicity induced by the multikinase inhibitor
sorafenib. Cardiovasc Toxicol. 10:1–8. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Semeniuk-Wojtaś A, Lubas A, Stec R,
Szczylik C and Niemczyk S: Influence of tyrosine kinase inhibitors
on hypertension and nephrotoxicity in metastatic renal cell cancer
patients. Int J Mol Sci. 17:20732016. View Article : Google Scholar
|
|
10
|
U.S. Department of Health and Human
Services, . Common Terminology Criteria For Adverse Events (CTCAE).
Version 5.0, 2017. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5×7.pdfNovember
27–2017
|
|
11
|
Bæk Møller N, Budolfsen C, Grimm D, Krüger
M, Infanger M, Wehland M and Magnusson N: Drug-induced hypertension
caused by multikinase inhibitors (sorafenib, sunitinib, lenvatinib
and axitinib) in renal cell carcinoma treatment. Int J Mol Sci.
20:47122019. View Article : Google Scholar
|
|
12
|
Tadic M, Cuspidi C, Belyavskiy E and
Grassi G: Intriguing relationship between antihypertensive therapy
and cancer. Pharmacol Res. 141:501–511. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pinter M, Kwanten WJ and Jain RK:
Renin-angiotensin system inhibitors to mitigate cancer
treatment-related adverse events. Clin Cancer Res. 24:3803–3812.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nakaya A, Kurata T, Yokoi T, Iwamoto S,
Torii Y, Katashiba Y, Ogata M, Hamada M, Kon M and Nomura S:
Retrospective analysis of bevacizumab-induced hypertension and
clinical outcome in patients with colorectal cancer and lung
cancer. Cancer Med. 5:1381–1387. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu X, Qin S, Wang Z, Xu J, Xiong J, Bai
Y, Wang Z, Yang Y, Sun G, Wang L, et al: Early presence of
anti-angiogenesis-related adverse events as a potential biomarker
of antitumor efficacy in metastatic gastric cancer patients treated
with apatinib: A cohort study. J Hematol Oncol. 10:1532017.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ravaud A, Motzer RJ, Pandha HS, George DJ,
Pantuck AJ, Patel A, Chang YH, Escudier B, Donskov F, Magheli A, et
al: Adjuvant sunitinib in high-risk renal-cell carcinoma after
nephrectomy. N Engl J Med. 375:2246–2254. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Escudier B, Pluzanska A, Koralewski P,
Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar
B, Bajetta E, et al: Bevacizumab plus interferon alfa-2a for
treatment of metastatic renal cell carcinoma: A randomised,
double-blind phase III trial. Lancet. 370:2103–2111. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Escudier B, Eisen T, Stadler WM, Szczylik
C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA,
et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N
Engl J Med. 356:125–134. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rini BI, Melichar B, Ueda T, Grünwald V,
Fishman MN, Arranz JA, Bair AH, Pithavala YK, Andrews GI, Pavlov D,
et al: Axitinib with or without dose titration for first-line
metastatic renal-cell carcinoma: A randomised double-blind phase 2
trial. Lancet Oncol. 14:1233–1242. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sternberg CN, Davis ID, Mardiak J,
Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA,
Kavina A, et al: Pazopanib in locally advanced or metastatic renal
cell carcinoma: Results of a randomized phase III trial. J Clin
Oncol. 28:1061–1068. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Akaza H, Naito S, Ueno N, Aoki K, Houzawa
H, Pitman Lowenthal S and Lee SY: Real-world use of sunitinib in
Japanese patients with advanced renal cell carcinoma: Efficacy,
safety and biomarker analyses in 1689 consecutive patients. Jpn J
Clin Oncol. 45:576–583. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rini BI, Halabi S, Rosenberg JE, Stadler
WM, Vaena DA, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J
and Small EJ: Phase III trial of bevacizumab plus interferon alfa
versus interferon alfa monotherapy in patients with metastatic
renal cell carcinoma: Final results of CALGB 90206. J Clin Oncol.
28:2137–2143. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ravaud A and Sire M: Arterial hypertension
and clinical benefit of sunitinib, sorafenib and bevacizumab in
first and second-line treatment of metastatic renal cell cancer.
Ann Oncol. 20:966–967. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Donskov F, Michaelson MD, Puzanov I, Davis
MP, Bjarnason GA, Motzer RJ, Goldstein D, Lin X, Cohen DP,
Wiltshire R and Rini BI: Sunitinib-associated hypertension and
neutropenia as efficacy biomarkers in metastatic renal cell
carcinoma patients. Br J Cancer. 113:1571–1580. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Goldstein D, Rosenberg JE, Figlin RA,
Townsend RR, McCann L, Carpenter C and Pandite L: Is change in
blood pressure a biomarker of pazopanib and sunitinib efficacy in
advanced/metastatic renal cell carcinoma? Eur J Cancer. 53:96–104.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li J, Qin S, Xu J, Guo W, Xiong J, Bai Y,
Sun G, Yang Y, Wang L, Xu N, et al: Apatinib for
chemotherapy-refractory advanced metastatic gastric cancer: Results
from a randomized, placebo-controlled, parallel-arm, phase II
trial. J Clin Oncol. 31:3219–3225. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fuchs CS, Tomasek J, Yong CJ, Dumitru F,
Passalacqua R, Goswami C, Safran H, Dos Santos LV, Aprile G, Ferry
DR, et al: Ramucirumab monotherapy for previously treated advanced
gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An
international, randomised, multicentre, placebo-controlled, phase 3
trial. Lancet. 383:31–39. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wilke H, Muro K, Van Cutsem E, Oh SC,
Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, et
al: Ramucirumab plus paclitaxel versus placebo plus paclitaxel in
patients with previously treated advanced gastric or
gastro-oesophageal junction adenocarcinoma (RAINBOW): A
double-blind, randomised phase 3 trial. Lancet Oncol. 15:1224–1235.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y,
Liu W, Tong J, Liu Y, Xu R, et al: Randomized, double-blind,
placebo-controlled phase III trial of apatinib in patients with
chemotherapy-refractory advanced or metastatic adenocarcinoma of
the stomach or gastroesophageal junction. J Clin Oncol.
34:1448–1454. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhou C, Wu YL, Chen G, Liu X, Zhu Y, Lu S,
Feng J, He J, Han B, Wang J, et al: BEYOND: A randomized,
double-blind, placebo-controlled, multicenter, phase III study of
first-line carboplatin/paclitaxel plus bevacizumab or placebo in
Chinese patients with advanced or recurrent nonsquamous
non-small-cell lung cancer. J Clin Oncol. 33:2197–2204. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sandler A, Gray R, Perry MC, Brahmer J,
Schiller JH, Dowlati A, Lilenbaum R and Johnson DH:
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell
lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Reck M, von Pawel J, Zatloukal P, Ramlau
R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N and
Manegold C: Phase III trial of cisplatin plus gemcitabine with
either placebo or bevacizumab as first-line therapy for nonsquamous
non-small-cell lung cancer: AVAil. J Clin Oncol. 27:1227–1234.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lu S, Chang J, Liu X, Shi J, Lu Y, Li W,
Yang JJ, Zhou J, Wang J, An T, et al: Randomized, double-blind,
placebo-controlled, multicenter phase II study of fruquintinib
after two prior chemotherapy regimens in chinese patients with
advanced nonsquamous nonsmall-cell lung cancer. J Clin Oncol.
36:1207–1217. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Saito H, Fukuhara T, Furuya N, Watanabe K,
Sugawara S, Iwasawa S, Tsunezuka Y, Yamaguchi O, Okada M, Yoshimori
K, et al: Erlotinib plus bevacizumab versus erlotinib alone in
patients with EGFR-positive advanced non-squamous non-small-cell
lung cancer (NEJ026): Interim analysis of an open-label,
randomised, multicentre, phase 3 trial. Lancet Oncol. 20:625–635.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhou M, Chen X, Zhang H, Xia L, Tong X,
Zou L, Hao R, Pan J, Zhao X, Chen D, et al: China national medical
products administration approval summary: Anlotinib for the
treatment of advanced non-small cell lung cancer after two lines of
chemotherapy. Cancer Commun (Lond). 39:362019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Goodwin R, Ding K, Seymour L, LeMaitre A,
Arnold A, Shepherd FA, Dediu M, Ciuleanu T, Fenton D, Zukin M, et
al: Treatment-emergent hypertension and outcomes in patients with
advanced non-small-cell lung cancer receiving chemotherapy with or
without the vascular endothelial growth factor receptor inhibitor
cediranib: NCIC clinical trials group study BR24. Ann Oncol.
21:2220–2226. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Koyama N: Adverse cardiovascular events
predict survival benefit in non-small lung cancer patients treated
with bevacizumab. Cancer Biomark. 14:259–265. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lin H, Li L, Luo S, Zhou S, Shen R, Yang
H, Chen H and Xie X: Efficacy and safety of angiogenesis inhibitors
in small-cell lung cancer. Oncology. 8:1141–1155. 2017.
|
|
39
|
Sun L, Ma JT, Zhang SL, Zou HW and Han CB:
Efficacy and safety of chemotherapy or tyrosine kinase inhibitors
combined with bevacizumab versus chemotherapy or tyrosine kinase
inhibitors alone in the treatment of non-small cell lung cancer: A
systematic review and meta-analysis. Med Oncol. 32:4732015.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Soria JC, Mauguen A, Reck M, Sandler AB,
Saijo N, Johnson DH, Burcoveanu D, Fukuoka M, Besse B and Pignon
JP; meta-analysis of bevacizumab in advanced NSCLC collaborative
group, : Systematic review and meta-analysis of randomised, phase
II/III trials adding bevacizumab to platinum-based chemotherapy as
first-line treatment in patients with advanced non-small-cell lung
cancer. Ann Oncol. 24:20–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Brahmer JR, Dahlberg SE, Gray RJ, Schiller
JH, Perry MC, Sandler A and Johnson DH: Sex differences in outcome
with bevacizumab therapy: Analysis of patients with advanced-stage
non-small cell lung cancer treated with or without bevacizumab in
combination with paclitaxel and carboplatin in the Eastern
cooperative oncology group trial 4599. J Thorac Oncol. 6:103–108.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Leighl NB, Zatloukal P, Mezger J, Ramlau
R, Moore N, Reck M and Manegold C: Efficacy and safety of
bevacizumab-based therapy in elderly patients with advanced or
recurrent nonsquamous non-small cell lung cancer in the phase III
BO17704 study (AVAiL). J Thorac Oncol. 5:1970–1976. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Price TJ, Zannino D, Wilson K, Simes RJ,
Cassidy J, Van Hazel GA, Robinson BA, Broad A, Ganju V, Ackland SP
and Tebbutt NC: Bevacizumab is equally effective and no more toxic
in elderly patients with advanced colorectal cancer: A subgroup
analysis from the AGITG MAX trial: An international randomised
controlled trial of capecitabine, bevacizumab and mitomycin C. Ann
Oncol. 23:1531–1536. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Aparicio T, Bouché O, Taieb J, Maillard E,
Kirscher S, Etienne PL, Faroux R, Khemissa Akouz F, El Hajbi F,
Locher C, et al: Bevacizumab+chemotherapy versus chemotherapy alone
in elderly patients with untreated metastatic colorectal cancer: A
randomized phase II trial-PRODIGE 20 study results. Ann Oncol.
29:133–138. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Allegra CJ, Yothers G, O'Connell MJ,
Sharif S, Colangelo LH, Lopa SH, Petrelli NJ, Goldberg RM, Atkins
JN, Seay TE, et al: Initial safety report of NSABP C-08: A
randomized phase III study of modified FOLFOX6 with or without
bevacizumab for the adjuvant treatment of patients with stage II or
III colon cancer. J Clin Oncol. 27:3385–3390. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Tabernero J, Yoshino T, Cohn AL,
Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy
DC, Van Cutsem E, Grothey A, et al: Ramucirumab versus placebo in
combination with second-line FOLFIRI in patients with metastatic
colorectal carcinoma that progressed during or after first-line
therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine
(RAISE): A randomised, double-blind, multicentre, phase 3 study.
Lancet Oncol. 16:499–508. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Grothey A, Cutsem EV, Sobrero A, Siena S,
Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, et al:
Regorafenib monotherapy for previously treated metastatic
colorectal cancer (CORRECT): An international, multicentre,
randomised, placebo-controlled, phase 3 trial. Lancet. 381:303–312.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Xu RH, Li J, Bai Y, Xu J, Liu T, Shen L,
Wang L, Pan H, Cao J, Zhang D, et al: Safety and efficacy of
fruquintinib in patients with previously treated metastatic
colorectal cancer: A phase Ib study and a randomized double-blind
phase II study. J Hematol Oncol. 10:222017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Scartozzi M, Galizia E, Chiorrini S,
Giampieri R, Berardi R, Pierantoni C and Cascinu S: Arterial
hypertension correlates with clinical outcome in colorectal cancer
patients treated with first-line bevacizumab. Ann Oncol.
20:227–230. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Tahover E, Uziely B, Salah A, Temper M,
Peretz T and Hubert A: Hypertension as a predictive biomarker in
bevacizumab treatment for colorectal cancer patients. Med Oncol.
30:3272013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
da Silva WC, de Araujo VE, Lima EMEA, Dos
Santos JBR, Silva MRRD, Almeida PHRF, de Assis Acurcio F, Godman B,
Kurdi A, Cherchiglia ML and Andrade EIG: Comparative effectiveness
and safety of monoclonal antibodies (bevacizumab, cetuximab, and
panitumumab) in combination with chemotherapy for metastatic
colorectal cancer: A systematic review and meta-analysis. BioDrugs.
32:585–606. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Hurwitz HI, Tebbutt NC, Kabbinavar F,
Giantonio BJ, Guan ZZ, Mitchell L, Waterkamp D and Tabernero J:
Efficacy and safety of bevacizumab in metastatic colorectal cancer:
Pooled analysis from seven randomized controlled trials.
Oncologist. 18:1004–1012. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Galfrascoli E, Piva S, Cinquini M, Rossi
A, La Verde N, Bramati A, Moretti A, Manazza A, Damia G, Torri V,
et al: Risk/benefit profile of bevacizumab in metastatic colon
cancer: A systematic review and meta-analysis. Dig Liver Dis.
43:286–294. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Tahover E, Hubert A, Temper M, Salah A,
Peretz T, Hamburger T and Uziely B: An observational cohort study
of bevacizumab and chemotherapy in metastatic colorectal cancer
patients: Safety and efficacy with analysis by age group. Target
Oncol. 10:55–63. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Tabernero J, Hozak RR, Yoshino T, Cohn AL,
Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy
DC, Prausová J, et al: Analysis of angiogenesis biomarkers for
ramucirumab efficacy in patients with metastatic colorectal cancer
from RAISE, a global, randomized, double-blind, phase III study.
Ann Oncol. 602–609. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Obermannová R, Van Cutsem E, Yoshino T,
Bodoky G, Prausová J, Garcia-Carbonero R, Ciuleanu T, Garcia
Alfonso P, Portnoy D, Cohn A, et al: Subgroup analysis in RAISE: A
randomized, double-blind phase III study of irinotecan, folinic
acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in
patients with metastatic colorectal carcinoma progression. Ann
Oncol. 27:2082–2090. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Cunningham D, Lang I, Marcuello E, Lorusso
V, Ocvirk J, Shin DB, Jonker D, Osborne S, Andre N, Waterkamp D, et
al: Bevacizumab plus capecitabine versus capecitabine alone in
elderly patients with previously untreated metastatic colorectal
cancer (AVEX): An open-label, randomised phase 3 trial. Lancet
Oncol. 14:1077–1085. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Shah SR, Gressett Ussery SM, Dowell JE,
Marley E, Liticker J, Arriaga Y and Verma U: Shorter bevacizumab
infusions do not increase the incidence of proteinuria and
hypertension. Ann Oncol. 24:960–965. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Li J, Qin S, Xu R, Yau TC, Ma B, Pan H, Xu
J, Bai Y, Chi Y, Wang L, et al: Regorafenib plus best supportive
care versus placebo plus best supportive care in Asian patients
with previously treated metastatic colorectal cancer (CONCUR): A
randomised, double-blind, placebo-controlled, phase 3 trial. Lancet
Oncol. 16:619–629. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Bennouna J, Sastre J, Arnold D, Österlund
P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C,
et al: Continuation of bevacizumab after first progression in
metastatic colorectal cancer (ML18147): A randomised phase 3 trial.
Lancet Oncol. 14:29–37. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Hegewisch-Becker S, Graeven U,
Lerchenmüller CA, Killing B, Depenbusch R, Steffens CC, Al-Batran
SE, Lange T, Dietrich G, Stoehlmacher J, et al: Maintenance
strategies after first-line oxaliplatin plus fluoropyrimidine plus
bevacizumab for patients with metastatic colorectal cancer (AIO
0207): A randomised, non-inferiority, open-label, phase 3 trial.
Lancet Oncol. 16:1355–1369. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Morse MA, Sun W, Kim R, He AR, Abada PB,
Mynderse M and Finn RS: The role of angiogenesis in hepatocellular
carcinoma. Clin Cancer Res. 25:912–920. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Abou-Alfa GK, Meyer T, Cheng AL,
El-Khoueiry AB, Rimassa L, Ryoo BY, Cicin I, Merle P, Chen Y, Park
JW, et al: Cabozantinib in patients with advanced and progressing
hepatocellular carcinoma. N Engl J Med. 379:54–63. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Bruix J, Qin S, Merle P, Granito A, Huang
YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, et al:
Regorafenib for patients with hepatocellular carcinoma who
progressed on sorafenib treatment (RESORCE): A randomised,
double-blind, placebo-controlled, phase 3 trial. Lancet. 389:56–66.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R,
Pastorelli D, Blanc JF, Chung HC, Baron AD, Pfiffer TE, et al:
Ramucirumab versus placebo as second-line treatment in patients
with advanced hepatocellular carcinoma following first-line therapy
with sorafenib (REACH): A randomised, double-blind, multicentre,
phase 3 trial. Lancet Oncol. 16:859–870. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Zhu AX, Kang YK, Yen CJ, Finn RS, Galle
PR, Llovet JM, Assenat E, Brandi G, Pracht M, Lim HY, et al:
Ramucirumab after sorafenib in patients with advanced
hepatocellular carcinoma and increased α-fetoprotein concentrations
(REACH-2): A randomised, double-blind, placebo-controlled, phase 3
trial. Lancet Oncol. 20:282–296. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Akutsu N, Sasaki S, Takagi H, Motoya M,
Shitani M, Igarashi M, Hirayama D, Wakasugi H, Yamamoto H, Kaneto
H, et al: Development of hypertension within 2 weeks of initiation
of sorafenib for advanced hepatocellular carcinoma is a predictor
of efficacy. Int J Clin Oncol. 20:105–110. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J
Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S,
Kim JS, Luo R, Feng J, Ye S, Yang TS, et al: Efficacy and safety of
sorafenib in patients in the Asia-Pacific region with advanced
hepatocellular carcinoma: A phase III randomised, double-blind,
placebo-controlled trial. Lancet Oncol. 10:25–34. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Meyer T, Fox R, Ma YT, Ross PJ, James MW,
Sturgess R, Stubbs C, Stocken DD, Wall L, Watkinson A, et al:
Sorafenib in combination with transarterial chemoembolisation in
patients with unresectable hepatocellular carcinoma (TACE 2): A
randomised placebo-controlled, double-blind, phase 3 trial. Lancet
Gastroenterol Hepatol. 2:565–575. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Aalders KC, Tryfonidis K, Senkus E and
Cardoso F: Anti- angiogenic treatment in breast cancer: Facts,
successes, failures and future perspectives. Cancer Treat Rev.
53:98–110. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Bear HD, Tang G, Rastogi P, Geyer CE Jr,
Robidoux A, Atkins JN, Baez-Diaz L, Brufsky AM, Mehta RS,
Fehrenbacher L, et al: Bevacizumab added to neoadjuvant
chemotherapy for breast cancer. N Engl J Med. 366:310–320. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Miles DW, Chan A, Dirix LY, Cortes J,
Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F,
et al: Phase III study of bevacizumab plus docetaxel compared with
placebo plus docetaxel for the first-line treatment of human
epidermal growth factor receptor 2-negative metastatic breast
cancer. J Clin Oncol. 28:3239–3247. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Robert NJ, Diéras V, Glaspy J, Brufsky AM,
Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SY, Zhou X, et
al: RIBBON-1: Randomized, double-blind, placebo-controlled, phase
III trial of chemotherapy with or without bevacizumab for
first-line treatment of human epidermal growth factor receptor
2-negative, locally recurrent or metastatic breast cancer. J Clin
Oncol. 29:1252–1260. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Fan M, Zhang J, Wang Z, Wang B, Zhang Q,
Zheng C, Li T, Ni C, Wu Z, Shao Z and Hu X: Phosphorylated VEGFR2
and hypertension: Potential biomarkers to indicate VEGF-dependency
of advanced breast cancer in anti-angiogenic therapy. Breast Cancer
Res Treat. 143:141–151. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Schneider BP, Wang M, Radovich M, Sledge
GW, Badve S, Thor A, Flockhart DA, Hancock B, Davidson N, Gralow J,
et al: Association of vascular endothelial growth factor and
vascular endothelial growth factor receptor-2 genetic polymorphisms
with outcome in a trial of paclitaxel compared with paclitaxel plus
bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol.
26:4672–4678. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Cortes J, Calvo V, Ramírez-Merino N,
O'Shaughnessy J, Brufsky A, Robert N, Vidal M, Muñoz E, Perez J,
Dawood S, et al: Adverse events risk associated with bevacizumab
addition to breast cancer chemotherapy: A meta-analysis. Ann Oncol.
23:1130–1137. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Pivot X, Schneeweiss A, Verma S, Thomssen
C, Passos-Coelho JL, Benedetti G, Ciruelos E, von Moos R, Chang HT,
Duenne AA and Miles DW: Efficacy and safety of bevacizumab in
combination with docetaxel for the first-line treatment of elderly
patients with locally recurrent or metastatic breast cancer:
Results from AVADO. Eur J Cancer. 47:2387–2395. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Rini BI, Powles T, Atkins MB, Escudier B,
McDermott DF, Suarez C, Bracarda S, Stadler WM, Donskov F, Lee JL,
et al: Atezolizumab plus bevacizumab versus sunitinib in patients
with previously untreated metastatic renal cell carcinoma
(IMmotion151): A multicentre, open-label, phase 3, randomised
controlled trial. Lancet. 393:2404–2415. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Yang L, Chen Y, Qin S, Wang L, Hua H, Liu
X, et al: Clinical observation on hypertenison induced by
anti-angiogenic agents for cancer. Chin Clin Oncol. 19:603–607.
2014.
|
|
81
|
Yang WY, Melgarejo JD, Thijs L, Zhang ZY,
Boggia J, Wei FF, Hansen TW, Asayama K, Ohkubo T, Jeppesen J, et
al: Association of office and ambulatory blood pressure with
mortality and cardiovascular outcomes. JAMA. 322:409–420. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Choueiri TK, Vaziri SAJ, Jaeger E, Elson
P, Wood L, Bhalla IP, Small EJ, Weinberg V, Sein N, Simko J, et al:
von Hippel-Lindau gene status and response to vascular endothelial
growth factor targeted therapy for metastatic clear cell renal cell
carcinoma. J Urol. 180:860–866. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Li Y, Li S, Zhu Y, Liang X, Meng H, Chen
J, Zhang D, Guo H and Shi B: Incidence and risk of
sorafenib-induced hypertension: A systematic review and
meta-analysis. J Clin Hypertens (Greenwich). 16:177–185. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Frey MK, Dao F, Olvera N, Konner JA,
Dickler MN and Levine DA: Genetic predisposition to
bevacizumab-induced hypertension. Gynecol Oncol. 147:621–625. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Scagliotti GV, Krzakowski M, Szczesna A,
Strausz J, Makhson A, Reck M, Wierzbicki RF, Albert I, Thomas M,
Miziara JE, et al: Sunitinib plus erlotinib versus placebo plus
erlotinib in patients with previously treated advanced
non-small-cell lung cancer: A phase III trial. J Clin Oncol.
30:2070–2078. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Shen L, Li J, Xu J, Pan H, Dai G, Qin S,
Wang L, Wang J, Yang Z, Shu Y, et al: Bevacizumab plus capecitabine
and cisplatin in Chinese patients with inoperable locally advanced
or metastatic gastric or gastroesophageal junction cancer:
Randomized, double-blind, phase III study (AVATAR study). Gastric
Cancer. 18:168–176. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Schwartzberg LS, Tauer KW, Hermann RC,
Makari-Judson G, Isaacs C, Beck JT, Kaklamani V, Stepanski EJ, Rugo
HS, Wang W, et al: Sorafenib or placebo with either gemcitabine or
capecitabine in patients with HER-2-negative advanced breast cancer
that progressed during or after bevacizumab. Clin Cancer Res.
19:2745–2754. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Crown JP, Diéras V, Staroslawska E,
Yardley DA, Bachelot T, Davidson N, Wildiers H, Fasching PA,
Capitain O, Ramos M, et al: Phase III trial of sunitinib in
combination with capecitabine versus capecitabine monotherapy for
the treatment of patients with pretreated metastatic breast cancer.
J Clin Oncol. 31:2870–2878. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Syrigos KN, Karapanagiotou E, Boura P,
Manegold C and Harrington K: Bevacizumab-induced hypertension:
Pathogenesis and management. BioDrugs. 25:159–169. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Williams B, Mancia G, Spiering W, Agabiti
Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G,
Dominiczak A, et al: 2018 ESC/ESH guidelines for the management of
arterial hypertension. Eur Heart J. 39:3021–3104. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Maitland ML, Bakris GL, Black HR, Chen HX,
Durand JB, Elliott WJ, Ivy SP, Leier CV, Lindenfeld J, Liu G, et
al: Initial assessment, surveillance, and management of blood
pressure in patients receiving vascular endothelial growth factor
signaling pathway inhibitors. J Natl Cancer Inst. 102:596–604.
2010. View Article : Google Scholar : PubMed/NCBI
|
